A SECRET WEAPON FOR INTEGRATIVE MEDICAL SERVICES BAY AREA

Iwasaki: Yeah, There are several things that we can easily be thinking of for much better accomplishment of clinical trials for very long COVID. So the first thing is the heterogeneity of disease and aquiring a validated biomarker going in to subclass the endotypes which i mentioned would drastically simplify the drug improvement and make it eye-c